Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma.

Journal of Cancer

Kraus TF, Greiner A, Steinmaurer M, Dietinger V, Guibourt V, Kretzschmar HA.
PMID: 26284134
J Cancer. 2015 Jul 15;6(9):832-42. doi: 10.7150/jca.12010. eCollection 2015.

The molecular mechanisms leading to brain tumors still remain unclear. Nevertheless, there is increasing evidence that epigenetic effects play crucial roles in tumor development and progression. Thereby, 5-hydroxymethylcytosine (5hmC) represents a further base modification of cytosine besides 5-methylcytosine (5mC)....

Cite
Kraus TF, Greiner A, Steinmaurer M, et al. Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. J Cancer. 2015;6(9):832-42doi: 10.7150/jca.12010.
Kraus, T. F., Greiner, A., Steinmaurer, M., Dietinger, V., Guibourt, V., & Kretzschmar, H. A. (2015). Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. Journal of Cancer, 6(9), 832-42. https://doi.org/10.7150/jca.12010
Kraus, Theo F J, et al. "Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma." Journal of Cancer vol. 6,9 (2015): 832-42. doi: https://doi.org/10.7150/jca.12010
Kraus TF, Greiner A, Steinmaurer M, Dietinger V, Guibourt V, Kretzschmar HA. Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. J Cancer. 2015 Jul 15;6(9):832-42. doi: 10.7150/jca.12010. eCollection 2015. PMID: 26284134; PMCID: PMC4532980.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2022). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2022): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.

Frontiers in oncology

Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C.
PMID: 34631593
Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021.

Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are predicted to derive high benefit from ICI but...

Cite
Varnier R, Garrivier T, Hafliger E, et al. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol. 2021;11:756365doi: 10.3389/fonc.2021.756365.
Varnier, R., Garrivier, T., Hafliger, E., Favre, A., Coutzac, C., Spire, C., Rochefort, P., Sarabi, M., Desseigne, F., Guibert, P., Cattey-Javouhey, A., Funk-Debleds, P., Mastier, C., Buisson, A., Pérol, D., Trédan, O., Blay, J. Y., Phelip, J. M., & de la Fouchardiere, C. (2021). Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Frontiers in oncology, 11756365. https://doi.org/10.3389/fonc.2021.756365
Varnier, Romain, et al. "Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report." Frontiers in oncology vol. 11 (2021): 756365. doi: https://doi.org/10.3389/fonc.2021.756365
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. PMID: 34631593; PMCID: PMC8499695.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.

Journal of molecular endocrinology

Lafont R, Serova M, Didry-Barca B, Raynal S, Guibout L, Dinan L, Veillet S, Latil M, Dioh W, Dilda PJ.
PMID: 34825653
J Mol Endocrinol. 2021 Dec 23;68(2):77-87. doi: 10.1530/JME-21-0033.

20-Hydroxyecdysone (20E) is a steroid hormone that plays a key role in insect development through nuclear ecdysteroid receptors (EcR/RXR complex) and at least one membrane GPCR receptor (DopEcR). It also displays numerous pharmacological effects in mammals, where its mechanism...

Cite
Lafont R, Serova M, Didry-Barca B, et al. 20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. J Mol Endocrinol. 2021;68(2):77-87doi: 10.1530/JME-21-0033.
Lafont, R., Serova, M., Didry-Barca, B., Raynal, S., Guibout, L., Dinan, L., Veillet, S., Latil, M., Dioh, W., & Dilda, P. J. (2021). 20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. Journal of molecular endocrinology, 68(2), 77-87. https://doi.org/10.1530/JME-21-0033
Lafont, René, et al. "20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor." Journal of molecular endocrinology vol. 68,2 (2021): 77-87. doi: https://doi.org/10.1530/JME-21-0033
Lafont R, Serova M, Didry-Barca B, Raynal S, Guibout L, Dinan L, Veillet S, Latil M, Dioh W, Dilda PJ. 20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. J Mol Endocrinol. 2021 Dec 23;68(2):77-87. doi: 10.1530/JME-21-0033. PMID: 34825653.
Copy Download .nbib Format: NLM
Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis.

Journal of dental research

Deraz O, Rangé H, Boutouyrie P, Chatzopoulou E, Asselin A, Guibout C, Van Sloten T, Bougouin W, Andrieu M, Vedié B, Thomas F, Danchin N, Jouven X, Bouchard P, Empana JP.
PMID: 34875909
J Dent Res. 2021 Dec 07;220345211052507. doi: 10.1177/00220345211052507. Epub 2021 Dec 07.

Poor oral health has been linked to coronary heart disease (CHD). Clustering clinical oral conditions routinely recorded in adults may identify their CHD risk profile. Participants from the Paris Prospective Study 3 received, between 2008 and 2012, a baseline...

Cite
Deraz O, Rangé H, Boutouyrie P, et al. Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis. J Dent Res. 2021;220345211052507doi: 10.1177/00220345211052507.
Deraz, O., Rangé, H., Boutouyrie, P., Chatzopoulou, E., Asselin, A., Guibout, C., Van Sloten, T., Bougouin, W., Andrieu, M., Vedié, B., Thomas, F., Danchin, N., Jouven, X., Bouchard, P., & Empana, J. P. (2021). Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis. Journal of dental research, 220345211052507. https://doi.org/10.1177/00220345211052507
Deraz, O, et al. "Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis." Journal of dental research vol. (2021): 220345211052507. doi: https://doi.org/10.1177/00220345211052507
Deraz O, Rangé H, Boutouyrie P, Chatzopoulou E, Asselin A, Guibout C, Van Sloten T, Bougouin W, Andrieu M, Vedié B, Thomas F, Danchin N, Jouven X, Bouchard P, Empana JP. Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis. J Dent Res. 2021 Dec 07;220345211052507. doi: 10.1177/00220345211052507. Epub 2021 Dec 07. PMID: 34875909.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Corrigendum to: Validation of a pneumatic tube system to transport surgical pathology biopsy samples.

Clinical chemistry and laboratory medicine

Guibourg B, Marcorelles P, Uguen A.
PMID: 29288617
Clin Chem Lab Med. 2018 Mar 28;56(4):681. doi: 10.1515/cclm-2017-1012.

No abstract available.

Cite
Guibourg B, Marcorelles P, Uguen A. Corrigendum to: Validation of a pneumatic tube system to transport surgical pathology biopsy samples. Clin Chem Lab Med. 2018;56(4):681doi: 10.1515/cclm-2017-1012.
Guibourg, B., Marcorelles, P., & Uguen, A. (2018). Corrigendum to: Validation of a pneumatic tube system to transport surgical pathology biopsy samples. Clinical chemistry and laboratory medicine, 56(4), 681. https://doi.org/10.1515/cclm-2017-1012
Guibourg, Briac, et al. "Corrigendum to: Validation of a pneumatic tube system to transport surgical pathology biopsy samples." Clinical chemistry and laboratory medicine vol. 56,4 (2018): 681. doi: https://doi.org/10.1515/cclm-2017-1012
Guibourg B, Marcorelles P, Uguen A. Corrigendum to: Validation of a pneumatic tube system to transport surgical pathology biopsy samples. Clin Chem Lab Med. 2018 Mar 28;56(4):681. doi: 10.1515/cclm-2017-1012. PMID: 29288617.
Copy Download .nbib Format: NLM
Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Oncology letters

Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C.
PMID: 28599496
Oncol Lett. 2017 Jun;13(6):4917-4924. doi: 10.3892/ol.2017.6061. Epub 2017 Apr 20.

There is a lack of prospective data about second-line treatments for metastatic pancreatic ductal adenocarcinoma patients. This is partially due to recent changes in first-line chemotherapy treatments. Despite this dearth of information, 50.0% of the patients who experience failure...

Cite
Sarabi M, Mais L, Oussaid N, et al. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13(6):4917-4924doi: 10.3892/ol.2017.6061.
Sarabi, M., Mais, L., Oussaid, N., Desseigne, F., Guibert, P., & De La Fouchardiere, C. (2017). Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncology letters, 13(6), 4917-4924. https://doi.org/10.3892/ol.2017.6061
Sarabi, Matthieu, et al. "Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma." Oncology letters vol. 13,6 (2017): 4917-4924. doi: https://doi.org/10.3892/ol.2017.6061
Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017 Jun;13(6):4917-4924. doi: 10.3892/ol.2017.6061. Epub 2017 Apr 20. PMID: 28599496; PMCID: PMC5453056.
Copy Download .nbib Format: NLM
Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma.

Journal of Cancer

Kraus TF, Greiner A, Guibourt V, Lisec K, Kretzschmar HA.
PMID: 25561975
J Cancer. 2015 Jan 01;6(2):111-9. doi: 10.7150/jca.10867. eCollection 2015.

BACKGROUND: Recent research indicates that long non-coding RNAs (lncRNA) represent a new family of RNAs that is of fundamental importance for controlling transcription and translation. Thereby, there is increasing evidence that lncRNAs are also important in tumourigenesis. Thereby valid...

Cite
Kraus TF, Greiner A, Guibourt V, et al. Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma. J Cancer. 2015;6(2):111-9doi: 10.7150/jca.10867.
Kraus, T. F., Greiner, A., Guibourt, V., Lisec, K., & Kretzschmar, H. A. (2015). Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma. Journal of Cancer, 6(2), 111-9. https://doi.org/10.7150/jca.10867
Kraus, Theo F J, et al. "Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma." Journal of Cancer vol. 6,2 (2015): 111-9. doi: https://doi.org/10.7150/jca.10867
Kraus TF, Greiner A, Guibourt V, Lisec K, Kretzschmar HA. Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma. J Cancer. 2015 Jan 01;6(2):111-9. doi: 10.7150/jca.10867. eCollection 2015. PMID: 25561975; PMCID: PMC4280393.
Copy Download .nbib Format: NLM
A2E-induced inflammation and angiogenesis in RPE cells .

Aging

Fontaine V, Fournié M, Monteiro E, Boumedine T, Balducci C, Guibout L, Latil M, Sahel JA, Veillet S, Dilda PJ, Lafont R, Camelo S.
PMID: 34544906
Aging (Albany NY). 2021 Sep 20;13(18):22040-22058. doi: 10.18632/aging.203558. Epub 2021 Sep 20.

No abstract available.

Cite
Fontaine V, Fournié M, Monteiro E, et al. A2E-induced inflammation and angiogenesis in RPE cells . Aging (Albany NY). 2021;13(18):22040-22058doi: 10.18632/aging.203558.
Fontaine, V., Fournié, M., Monteiro, E., Boumedine, T., Balducci, C., Guibout, L., Latil, M., Sahel, J. A., Veillet, S., Dilda, P. J., Lafont, R., & Camelo, S. (2021). A2E-induced inflammation and angiogenesis in RPE cells . Aging, 13(18), 22040-22058. https://doi.org/10.18632/aging.203558
Fontaine, Valérie, et al. "A2E-induced inflammation and angiogenesis in RPE cells ." Aging vol. 13,18 (2021): 22040-22058. doi: https://doi.org/10.18632/aging.203558
Fontaine V, Fournié M, Monteiro E, Boumedine T, Balducci C, Guibout L, Latil M, Sahel JA, Veillet S, Dilda PJ, Lafont R, Camelo S. A2E-induced inflammation and angiogenesis in RPE cells . Aging (Albany NY). 2021 Sep 20;13(18):22040-22058. doi: 10.18632/aging.203558. Epub 2021 Sep 20. PMID: 34544906; PMCID: PMC8507260.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries